Literature DB >> 35522310

[Everyday transgressions of borderlines: the scandalization of clinical drug trials of the psychiatrist Roland Kuhn].

Hanfried Helmchen1.   

Abstract

"Experimental case Münsterlingen: clinical trials in psychiatry, 1940-1980" is the name of the report of a control commission established by the government of the Swiss Canton Thurgau in 2016, after several articles in the press after 2012 had criticized the drug tests carried out by Roland Kuhn, the former clinical director of the cantonal mental hospital in Münsterlingen. The report discusses "fine discrepancies in everyday borderline transgressions" "from today's viewpoint". These borderline transgressions were seen especially in the missing, inadequate or undocumented informed consent of patients and in the usage of test substances, which varied between the (mostly) accepted or not refused intake and the camouflaged or (seldom) threatened application via injection. Thus, the report shows on the one hand, the considerable development of the normative context of treatment of mentally ill patients in the past 70 years and on the other hand, with its detailed descriptions, it can sensitize today's therapists to the pertinent context. But most of all this is the story of Roland Kuhn, the responsible psychiatrist and the drug testing discoverer of the antidepressive effect of imipramine. This story of the discovery is judged from very differing perspectives and is thus relativized, all the way from observations of a "provincial psychiatrist" to consideration for the Nobel Prize. At the same time critically evaluated traits of Kuhn's personality seem to have influenced the occasionally negative comments of the commission report. We should recognize, however, that with his qualitative and psychopathological individual case observations, Kuhn discovered the antidepressive effect of a test substance that as a hypothesis was verified by subsequent quantitative and statistical methods.
© 2022. The Author(s).

Entities:  

Keywords:  Antidepressive effect; Clinical drug tests; Historical bias of evaluation; Informed consent; Misbehaviour

Year:  2022        PMID: 35522310     DOI: 10.1007/s00115-022-01296-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  9 in total

1.  Laying ethical foundations for clinical research.

Authors:  J Harkness; S E Lederer; D Wikler
Journal:  Bull World Health Organ       Date:  2003-07-02       Impact factor: 9.408

2.  [Treatment of depressive states with an iminodibenzyl derivative (G 22355)].

Authors:  R KUHN
Journal:  Schweiz Med Wochenschr       Date:  1957-08-31

3.  Clinical experience with iproniazid (marsilid).

Authors:  N S KLINE
Journal:  J Clin Exp Psychopathol       Date:  1958 Apr-Jun

4.  The clinical discovery of imipramine.

Authors:  Walter A Brown; Maria Rosdolsky
Journal:  Am J Psychiatry       Date:  2015-05       Impact factor: 18.112

Review 5.  Roland Kuhn-100th Birthday of an Innovator of Clinical Psychopharmacology.

Authors:  Holger Steinberg; Hubertus Himmerich
Journal:  Psychopharmacol Bull       Date:  2012-02-15

6.  Final report on the "Tuskegee syphilis study".

Authors:  R H Kampmeier
Journal:  South Med J       Date:  1974-11       Impact factor: 0.954

7.  Ethics and clinical research.

Authors:  H K Beecher
Journal:  N Engl J Med       Date:  1966-06-16       Impact factor: 91.245

8.  Informed consent in human experimentation before the Nuremberg code.

Authors:  J Vollmann; R Winau
Journal:  BMJ       Date:  1996-12-07

9.  The New Era of Informed Consent: Getting to a Reasonable-Patient Standard Through Shared Decision Making.

Authors:  Erica S Spatz; Harlan M Krumholz; Benjamin W Moulton
Journal:  JAMA       Date:  2016-05-17       Impact factor: 56.272

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.